Pharmerit International is pleased to welcome Kelly McCarrier, who will join Pharmerit as Director and US Qualitative Lead within the Patient-Reported Outcomes and Clinical Outcomes Assessment Center of Excellence. In this role, Kelly will serve as a leader in the continued growth of Pharmerit through leading innovative qualitative research projects in concert with our team of PRO/COA researchers.
Kelly joins Pharmerit from Health Research Associates, where he has over a decade of experience in qualitative and mixed-methods development and evaluation of COA tools. Since joining HRA in 2006, he has served as a principal investigator, coordinator, qualitative interviewer, analyst, and research methodologist on nearly 100 projects to develop and validate PRO instruments across a broad spectrum of health conditions. Recently, Kelly has helped to lead HRA’s instrument-development collaborations with both the Depression and Lung Cancer Working Groups of the PRO Consortium, resulting in the organization’s first two successful FDA qualifications of outcome assessment tools (the Symptoms of Major Depressive Disorder Scale[SMDDS] and the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire[NSCLC-SAQ]).
Dr. McCarrier received his PhD in Health Services Research from the University of Washington, and his MPH from the University of Arizona. Before beginning his doctoral studies, he served as an evaluation research fellow with the Centers for Disease Control and Prevention (CDC), conducting qualitative research and program evaluation projects within the Division of Tuberculosis Elimination. Kelly is a member of ISOQOL and ISPOR, and has authored several recent publications/presentations on the use of novel qualitative research techniques and mixed-methods approaches in the development and evaluation of PRO instruments.
We are excited to have Kelly join Pharmerit in August, 2018.